Financial Performance - The company's revenue for Q1 2022 was CNY 2,102,899,933.93, representing a 41.19% increase compared to CNY 1,489,385,309.64 in the same period last year[4]. - Net profit attributable to shareholders was CNY 249,086,573.60, a slight increase of 1.31% from CNY 245,874,010.35 year-on-year[4]. - The net profit excluding non-recurring gains and losses was CNY 310,563,849.47, reflecting a 30.83% increase from CNY 237,376,010.22 in the previous year[4]. - Operating revenue for the reporting period reached ¥2,102,899,933.93, an increase of 41.19% compared to ¥1,489,385,309.64 in the same period last year[9]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥310,563,849.47, reflecting a growth of 30.83% from ¥237,376,010.22 year-on-year[9]. - The company reported a total profit of $316.18 million, compared to $282.48 million in the previous period, marking an increase of 11.96%[34]. - The adjusted net profit attributable to the parent company for the first quarter of 2022 was RMB 364,396 thousand, a significant increase of 39.1% year-over-year[47]. Cash Flow and Assets - The company's cash flow from operating activities was CNY 417,792,056.81, down 16.27% from CNY 498,953,761.05 in the same quarter last year[4]. - The total assets at the end of the reporting period were CNY 18,660,920,785.51, a 1.48% increase from CNY 18,389,124,353.35 at the end of the previous year[4]. - The company has shown a strong increase in cash and cash equivalents, with current assets totaling CNY 7,646,204,942.02, down from CNY 8,643,502,127.97, indicating a decrease of about 11.5%[22]. - The company’s cash and cash equivalents were RMB 2,873,493 thousand as of March 31, 2022, down from RMB 3,526,577 thousand at the end of 2021, indicating a decrease of about 18.5%[43]. Expenses and Liabilities - The company's cash flow from financing activities is -$298.11 million, a decrease from $285.02 million in the previous period, indicating a decline of 204.73%[41]. - Operating costs increased by 44.77% to ¥1,407,271,726.88, aligning with the revenue growth[10]. - The company reported a significant rise in financial expenses, up 416.87% to ¥40,234,145.81, primarily due to increased interest expenses[11]. - Total liabilities increased to CNY 8,316,165,204.05 from CNY 8,093,817,609.58, reflecting a rise of approximately 2.8%[26]. Shareholder Information - The top ten shareholders hold a combined 66.77% of the company's shares, with the largest shareholder owning 18.68%[12]. - The top ten unrestricted shareholders hold a total of 448,000,000 shares, with Shenzhen Xinchongkang Investment Partnership holding the largest share of 148,335,300 shares[14]. - The company’s major shareholders include individuals with significant connections, such as Mr. Lou Xiaoqiang, who holds 100% of Ningbo Longtai Kang Investment Management Co., Ltd.[15]. Research and Development - Research and development expenses increased by 36.27% to ¥39,647,299.50 from ¥29,095,136.05 year-on-year, indicating a commitment to enhancing R&D capabilities[11]. - The company reported a net investment loss of CNY 7,402,982.10 from joint ventures and associates, compared to a loss of CNY 344,610.97 in the previous period[77]. Acquisitions and Integrations - The company completed the acquisition of Aesica Pharmaceuticals Limited for approximately £55 million (around RMB 47.34 million), enhancing its CDMO service capabilities[18]. - The integration of clinical research services through Kanglong Chemical (Chengdu) Clinical Research Service Co., Ltd. aims to optimize clinical R&D capabilities and improve service quality[19]. Government Support - The company received government subsidies amounting to CNY 9,391,153.38 during the reporting period[6].
康龙化成(03759) - 2022 Q1 - 季度财报